Current and novel antiviral strategies for influenza infection

Current Opinion in Virology

Volumn 18, Issue , 2016, Pages 126-134

  Yen, Hui Ling ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; ANTIVIRUS AGENT; CAP BINDING PROTEIN; ENDONUCLEASE; FAVIPIRAVIR; IMMUNOMODULATING AGENT; L 742001; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; RIMANTADINE; UNCLASSIFIED DRUG; VX 787; ZANAMIVIR; AMIDE; ENZYME INHIBITOR; NUCLEOPROTEIN; PYRAZINE DERIVATIVE; SIALIDASE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; COMBINATION DRUG THERAPY; DRUG APPROVAL; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INFLUENZA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; METABOLISM; RESPIRATORY TRACT INFECTIONS; VIROLOGY; VIRUS REPLICATION;

AMIDES; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; NEURAMINIDASE; NUCLEOPROTEINS; PYRAZINES; RESPIRATORY TRACT INFECTIONS; VIRUS REPLICATION;

EID: 84975796039     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.05.004     Document Type: Review

References (99)

1. S.J. Gamblin, and J.J. Skehel Influenza hemagglutinin and neuraminidase membrane glycoproteins J Biol Chem 285 2010 28403 28409
2. E. van der Vries, E.J. Veldhuis Kroeze, K.J. Stittelaar, M. Linster, A. Van der Linden, E.J. Schrauwen, L.M. Leijten, G. van Amerongen, M. Schutten, T. Kuiken, and et al. Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets PLoS Pathog 7 2011 e1002276
3. J.J. Skehel, and D.C. Wiley Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin Annu Rev Biochem 69 2000 531 569
4. P. Resa-Infante, N. Jorba, R. Coloma, and J. Ortin The influenza virus RNA synthesis machine: advances in its structure and function RNA Biol 8 2011 207 215
5. D.P. Nayak, R.A. Balogun, H. Yamada, Z.H. Zhou, and S. Barman Influenza virus morphogenesis and budding Virus Res 143 2009 147 161
6. J. Dunning, J.K. Baillie, B. Cao, F.G. Hayden, and Consortium ISAREI Antiviral combinations for severe influenza Lancet Infect Dis 14 2014 1259 1270
7. N.P. Johnson, and J. Mueller Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic Bull Hist Med 76 2002 105 115
8. R.M. Pielak, and J.J. Chou Influenza M2 proton channels Biochim Biophys Acta 1808 2011 522 529
9. F.G. Hayden, R.B. Belshe, R.D. Clover, A.J. Hay, M.G. Oakes, and W. Soo Emergence and apparent transmission of rimantadine-resistant influenza A virus in families N Engl J Med 321 1989 1696 1702
10. V.M. Deyde, X. Xu, R.A. Bright, M. Shaw, C.B. Smith, Y. Zhang, Y. Shu, L.V. Gubareva, N.J. Cox, and A.I. Klimov Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide J Infect Dis 196 2007 249 257
11. R.A. Bright, M.J. Medina, X. Xu, G. Perez-Oronoz, T.R. Wallis, X.M. Davis, L. Povinelli, N.J. Cox, and A.I. Klimov Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern Lancet 366 2005 1175 1181
12. L.V. Gubareva, A.A. Trujillo, M. Okomo-Adhiambo, V.P. Mishin, V.M. Deyde, K. Sleeman, H.T. Nguyen, T.G. Sheu, R.J. Garten, M.W. Shaw, and et al. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro Antivir Ther 15 2010 1151 1159
13. M.G. Alves Galvao, M.A. Rocha Crispino Santos, and A.J. Alves da Cunha Amantadine and rimantadine for influenza A in children and the elderly Cochrane Database Syst Rev 11 2014 CD002745
14. W.P. Burmeister, R.W. Ruigrok, and S. Cusack The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid EMBO J 11 1992 49 56
15. G.M. Air Influenza neuraminidase Influenza Other Respir Viruses 6 2012 245 256
16. R.J. Russell, L.F. Haire, D.J. Stevens, P.J. Collins, Y.P. Lin, G.M. Blackburn, A.J. Hay, S.J. Gamblin, and J.J. Skehel The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design Nature 443 2006 45 49
17. P.M. Colman, P.A. Hoyne, and M.C. Lawrence Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase J Virol 67 1993 2972 2980
18. P.M. Colman Neuraminidase inhibitors as antivirals Vaccine 20 Suppl 2 2002 S55 S58
19. P. Meindl, G. Bodo, P. Palese, J. Schulman, and H. Tuppy Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid Virology 58 1974 457 463
20. P.M. Colman Influenza virus neuraminidase: structure, antibodies, and inhibitors Protein Sci 3 1994 1687 1696
21. P.M. Colman, J.N. Varghese, and W.G. Laver Structure of the catalytic and antigenic sites in influenza virus neuraminidase Nature 303 1983 41 44
22. J.N. Varghese, W.G. Laver, and P.M. Colman Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution Nature 303 1983 35 40
23. M. von Itzstein The war against influenza: discovery and development of sialidase inhibitors Nat Rev Drug Discov 6 2007 967 974
24. M. von Itzstein, W.Y. Wu, G.B. Kok, M.S. Pegg, J.C. Dyason, B. Jin, T. Van Phan, M.L. Smythe, H.F. White, S.W. Oliver, and et al. Rational design of potent sialidase-based inhibitors of influenza virus replication Nature 363 1993 418 423
25. C.U. Kim, W. Lew, M.A. Williams, H. Liu, L. Zhang, S. Swaminathan, N. Bischofberger, M.S. Chen, D.B. Mendel, C.Y. Tai, and et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity J Am Chem Soc 119 1997 681 690
26. Y.S. Babu, P. Chand, S. Bantia, P. Kotian, A. Dehghani, Y. El-Kattan, T.H. Lin, T.L. Hutchison, A.J. Elliott, C.D. Parker, and et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design J Med Chem 43 2000 3482 3486
27. J.N. Varghese, P.W. Smith, S.L. Sollis, T.J. Blick, A. Sahasrabudhe, J.L. McKimm-Breschkin, and P.M. Colman Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase Structure 6 1998 735 746
28. J.L. McKimm-Breschkin Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance Influenza Other Respir Viruses 7 Suppl 1 2013 25 36
29. M.M. McLaughlin, E.W. Skoglund, and M.G. Ison Peramivir: an intravenous neuraminidase inhibitor Expert Opin Pharmacother 16 2015 1889 1900
30. S. Kubo, T. Tomozawa, M. Kakuta, A. Tokumitsu, and M. Yamashita Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration Antimicrob Agents Chemother 54 2010 1256 1264
31. M. Yamashita, T. Tomozawa, M. Kakuta, A. Tokumitsu, H. Nasu, and S. Kubo CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity Antimicrob Agents Chemother 53 2009 186 192
32. J.H. Kim, R. Resende, T. Wennekes, H.M. Chen, N. Bance, S. Buchini, A.G. Watts, P. Pilling, V.A. Streltsov, M. Petric, and et al. Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity Science 340 2013 71 75
33. A. Meijer, H. Rebelo-de-Andrade, V. Correia, T. Besselaar, R. Drager-Dayal, A. Fry, V. Gregory, L. Gubareva, T. Kageyama, A. Lackenby, and et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013 Antivir Res 110 2014 31 41
34. C.J. Vavricka, Q. Li, Y. Wu, J. Qi, M. Wang, Y. Liu, F. Gao, J. Liu, E. Feng, J. He, and et al. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition PLoS Pathog 7 2011 e1002249
35. S. Fujisaki, E. Takashita, M. Yokoyama, T. Taniwaki, H. Xu, N. Kishida, H. Sato, M. Tashiro, M. Imai, and T. Odagiri A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs Biochem Biophys Res Commun 429 2012 51 56
36. E. Takashita, A. Meijer, A. Lackenby, L. Gubareva, H. Rebelo-de-Andrade, T. Besselaar, A. Fry, V. Gregory, S.K. Leang, W. Huang, and et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014 Antivir Res 117 2015 27 38
37. Q.M. Le, M. Kiso, K. Someya, Y.T. Sakai, T.H. Nguyen, K.H. Nguyen, N.D. Pham, H.H. Ngyen, S. Yamada, Y. Muramoto, and et al. Avian flu: isolation of drug-resistant H5N1 virus Nature 437 2005 1108
38. M. Kiso, K. Mitamura, Y. Sakai-Tagawa, K. Shiraishi, C. Kawakami, K. Kimura, F.G. Hayden, N. Sugaya, and Y. Kawaoka Resistant influenza A viruses in children treated with oseltamivir: descriptive study Lancet 364 2004 759 765
39. V. Escuret, P.J. Collins, J.S. Casalegno, S.G. Vachieri, N. Cattle, O. Ferraris, M. Sabatier, E. Frobert, V. Caro, J.J. Skehel, and et al. A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses J Infect Dis 210 2014 1260 1269
40. L.V. Gubareva, M.N. Matrosovich, M.K. Brenner, R.C. Bethell, and R.G. Webster Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus J Infect Dis 178 1998 1257 1262
41. M.G. Ison, L.V. Gubareva, R.L. Atmar, J. Treanor, and F.G. Hayden Recovery of drug-resistant influenza virus from immunocompromised patients: a case series J Infect Dis 193 2006 760 764
42. WHO: Summary of Neuraminidase Amino Acid Substitutions Associated with Reduced Inhibition by Neuraminidase Inhibitors (NAI) (http://www.who.int/influenza/gisrs
43. F. Hayden Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 48 Suppl 1 2009 S3 S13
44. N.A. Roberts Treatment of influenza with neuraminidase inhibitors: virological implications Philos Trans R Soc Lond B Biol Sci 356 2001 1895 1897
45. R.J. Whitley, C.A. Boucher, B. Lina, J.S. Nguyen-Van-Tam, A. Osterhaus, M. Schutten, and A.S. Monto Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS) Clin Infect Dis 56 2013 1197 1205
46. R.J. Whitley, F.G. Hayden, K.S. Reisinger, N. Young, R. Dutkowski, D. Ipe, R.G. Mills, and P. Ward Oral oseltamivir treatment of influenza in children Pediatr Infect Dis J 20 2001 127 133
47. M. Baz, Y. Abed, J. McDonald, and G. Boivin Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child Clin Infect Dis 43 2006 1555 1561
48. A. Eshaghi, S. Shalhoub, P. Rosenfeld, A. Li, R.R. Higgins, P.J. Stogios, A. Savchenko, N. Bastien, Y. Li, C. Rotstein, and et al. Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient Antimicrob Agents Chemother 58 2014 7188 7197
49. M.J. Memoli, R. Athota, S. Reed, L. Czajkowski, T. Bristol, K. Proudfoot, R. Hagey, J. Voell, C. Fiorentino, A. Ademposi, and et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts Clin Infect Dis 58 2014 214 224
50. A. Piralla, M. Gozalo-Marguello, L. Fiorina, F. Rovida, A. Muzzi, A.A. Colombo, P.E. Alessandrino, and F. Baldanti Different drug-resistant influenza A(H3N2) variants in two immunocompromised patients treated with oseltamivir during the 2011-2012 influenza season in Italy J Clin Virol 58 2013 132 137
51. D.M. Weinstock, L.V. Gubareva, and G. Zuccotti Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient N Engl J Med 348 2003 867 868
52. D. Tamura, R.L. DeBiasi, M. Okomo-Adhiambo, V.P. Mishin, A.P. Campbell, B. Loechelt, B.L. Wiedermann, A.M. Fry, and L.V. Gubareva Emergence of multidrug-resistant influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir J Infect Dis 212 2015 1209 1213
53. J.D. Bloom, L.I. Gong, and D. Baltimore Permissive secondary mutations enable the evolution of influenza oseltamivir resistance Science 328 2010 1272 1275
54. S. Duan, E.A. Govorkova, J. Bahl, H. Zaraket, T. Baranovich, P. Seiler, K. Prevost, R.G. Webster, and R.J. Webby Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses Nat Commun 5 2014 5029
55. Y. Abed, A. Pizzorno, X. Bouhy, and G. Boivin Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses PLoS Pathog 7 2011 e1002431
56. M.A. Rameix-Welti, S. Munier, S. Le Gal, F. Cuvelier, F. Agou, V. Enouf, N. Naffakh, and S. van der Werf Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344 N substitution Antivir Ther 16 2011 597 603
57. F.Y. Aoki, M.D. Macleod, P. Paggiaro, O. Carewicz, A. El Sawy, C. Wat, M. Griffiths, E. Waalberg, P. Ward, and I.S. Group Early administration of oral oseltamivir increases the benefits of influenza treatment J Antimicrob Chemother 51 2003 123 129
58. N. Lee, Y.S. Leo, B. Cao, P.K. Chan, W.M. Kyaw, T.M. Uyeki, W.W. Tam, C.S. Cheung, I.M. Yung, H. Li, and et al. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients Eur Respir J 45 2015 1642 1652
59. S.G. Muthuri, S. Venkatesan, P.R. Myles, J. Leonardi-Bee, T.S. Al Khuwaitir, A. Al Mamun, A.P. Anovadiya, E. Azziz-Baumgartner, C. Baez, M. Bassetti, and et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data Lancet Respir Med 2 2014 395 404
60. J. Dobson, R.J. Whitley, S. Pocock, and A.S. Monto Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials Lancet 385 2015 1729 1737
61. T. Jefferson, M. Jones, P. Doshi, E.A. Spencer, I. Onakpoya, and C.J. Heneghan Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments BMJ 348 2014 g2545
62. C.J. Heneghan, I. Onakpoya, M. Thompson, E.A. Spencer, M. Jones, and T. Jefferson Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments BMJ 348 2014 g2547
63. Y. Furuta, B.B. Gowen, K. Takahashi, K. Shiraki, D.F. Smee, and D.L. Barnard Favipiravir (T-705), a novel viral RNA polymerase inhibitor Antivir Res 100 2013 446 454
64. H. Sangawa, T. Komeno, H. Nishikawa, A. Yoshida, K. Takahashi, N. Nomura, and Y. Furuta Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase Antimicrob Agents Chemother 57 2013 5202 5208
65. T. Baranovich, S.S. Wong, J. Armstrong, H. Marjuki, R.J. Webby, R.G. Webster, and E.A. Govorkova T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro J Virol 87 2013 3741 3751
66. A. Arias, L. Thorne, and I. Goodfellow Favipiravir elicits antiviral mutagenesis during virus replication in vivo Elife 3 2014 e03679
67. L. Delang, N. Segura Guerrero, A. Tas, G. Querat, B. Pastorino, M. Froeyen, K. Dallmeier, D. Jochmans, P. Herdewijn, F. Bello, and et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral J Antimicrob Chemother 69 2014 2770 2784
68. T. Nagata, A.K. Lefor, M. Hasegawa, and M. Ishii Favipiravir: a new medication for the Ebola virus disease pandemic Disaster Med Public Health Prep 9 2015 79 81
69. R.W. Sidwell, J.H. Huffman, G.P. Khare, L.B. Allen, J.T. Witkowski, and R.K. Robins Broad-spectrum antiviral activity of Virazole: 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide Science 177 1972 705 706
70. A. Pflug, D. Guilligay, S. Reich, and S. Cusack Structure of influenza A polymerase bound to the viral RNA promoter Nature 516 2014 355 360
71. S. Reich, D. Guilligay, A. Pflug, H. Malet, I. Berger, T. Crepin, D. Hart, T. Lunardi, M. Nanao, R.W. Ruigrok, and et al. Structural insight into cap-snatching and RNA synthesis by influenza polymerase Nature 516 2014 361 366
72. Q. Ye, R.M. Krug, and Y.J. Tao The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA Nature 444 2006 1078 1082
73. S.W. Gerritz, C. Cianci, S. Kim, B.C. Pearce, C. Deminie, L. Discotto, B. McAuliffe, B.F. Minassian, S. Shi, S. Zhu, and et al. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers Proc Natl Acad Sci U S A 108 2011 15366 15371
74. R.Y. Kao, D. Yang, L.S. Lau, W.H. Tsui, L. Hu, J. Dai, M.P. Chan, C.M. Chan, P. Wang, B.J. Zheng, and et al. Identification of influenza A nucleoprotein as an antiviral target Nat Biotechnol 28 2010 600 605
75. C.Y. Su, T.J. Cheng, M.I. Lin, S.Y. Wang, W.I. Huang, S.Y. Lin-Chu, Y.H. Chen, C.Y. Wu, M.M. Lai, W.C. Cheng, and et al. High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity Proc Natl Acad Sci U S A 107 2010 19151 19156
76. Y.F. Shen, Y.H. Chen, S.Y. Chu, M.I. Lin, H.T. Hsu, P.Y. Wu, C.J. Wu, H.W. Liu, F.Y. Lin, G. Lin, and et al. E339...R416 salt bridge of nucleoprotein as a feasible target for influenza virus inhibitors Proc Natl Acad Sci U S A 108 2011 16515 16520
77. N. Lejal, B. Tarus, E. Bouguyon, S. Chenavas, N. Bertho, B. Delmas, R.W. Ruigrok, C. Di Primo, and A. Slama-Schwok Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus Antimicrob Agents Chemother 57 2013 2231 2242
78. M. Kakisaka, Y. Sasaki, K. Yamada, Y. Kondoh, H. Hikono, H. Osada, K. Tomii, T. Saito, and Y. Aida A novel antiviral target structure involved in the RNA binding, dimerization, and nuclear export functions of the influenza A virus nucleoprotein PLoS Pathog 11 2015 e1005062
79. J. Reguera, P. Gerlach, and S. Cusack Towards a structural understanding of RNA synthesis by negative strand RNA viral polymerases Curr Opin Struct Biol 36 2016 75 84
80. M.P. Clark, M.W. Ledeboer, I. Davies, R.A. Byrn, S.M. Jones, E. Perola, A. Tsai, M. Jacobs, K. Nti-Addae, U.K. Bandarage, and et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2 J Med Chem 57 2014 6668 6678
81. R.A. Byrn, S.M. Jones, H.B. Bennett, C. Bral, M.P. Clark, M.D. Jacobs, A.D. Kwong, M.W. Ledeboer, J.R. Leeman, C.F. McNeil, and et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit Antimicrob Agents Chemother 59 2015 1569 1582
82. J.L. McKimm-Breschkin, and A.M. Fry Meeting report: 4th ISIRV antiviral group conference: novel antiviral therapies for influenza and other respiratory viruses Antivir Res 129 2016 21 38
83. E. Kowalinski, C. Zubieta, A. Wolkerstorfer, O.H. Szolar, R.W. Ruigrok, and S. Cusack Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase PLoS Pathog 8 2012 e1002831
84. J. Tomassini, H. Selnick, M.E. Davies, M.E. Armstrong, J. Baldwin, M. Bourgeois, J. Hastings, D. Hazuda, J. Lewis, W. McClements, and et al. Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds Antimicrob Agents Chemother 38 1994 2827 2837
85. R.M. DuBois, P.J. Slavish, B.M. Baughman, M.K. Yun, J. Bao, R.J. Webby, T.R. Webb, and S.W. White Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease PLoS Pathog 8 2012 e1002830
86. A. Stevaert, R. Dallocchio, A. Dessi, N. Pala, D. Rogolino, M. Sechi, and L. Naesens Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease J Virol 87 2013 10524 10538
87. X. Duval, S. van der Werf, T. Blanchon, A. Mosnier, M. Bouscambert-Duchamp, A. Tibi, V. Enouf, C. Charlois-Ou, C. Vincent, L. Andreoletti, and et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial PLoS Med 7 2010 e1000362
88. V. Escuret, C. Cornu, F. Boutitie, V. Enouf, A. Mosnier, M. Bouscambert-Duchamp, S. Gaillard, X. Duval, T. Blanchon, C. Leport, and et al. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections Antivir Res 96 2012 130 137
89. D.F. Smee, B.L. Hurst, M.H. Wong, K.W. Bailey, E.B. Tarbet, J.D. Morrey, and Y. Furuta Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice Antimicrob Agents Chemother 54 2010 126 133
90. S. Park, J.I. Kim, I. Lee, S. Lee, M.W. Hwang, J.Y. Bae, J. Heo, D. Kim, S.I. Jang, H. Kim, and et al. Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice PLOS ONE 9 2014 e101325
91. N.A. Ilyushina, A. Hay, N. Yilmaz, A.C. Boon, R.G. Webster, and E.A. Govorkova Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice Antimicrob Agents Chemother 52 2008 3889 3897
92. N.A. Ilyushina, E. Hoffmann, R. Salomon, R.G. Webster, and E.A. Govorkova Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice Antivir Ther 12 2007 363 370
93. D.F. Smee, B.L. Hurst, M.H. Wong, K.W. Bailey, and J.D. Morrey Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice Antimicrob Agents Chemother 53 2009 2120 2128
94. Y. Hu, S. Lu, Z. Song, W. Wang, P. Hao, J. Li, X. Zhang, H.L. Yen, B. Shi, T. Li, and et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance Lancet 381 2013 2273 2279
95. A.C. Hurt The epidemiology and spread of drug resistant human influenza viruses Curr Opin Virol 8 2014 22 29
96. G. Tang, X. Lin, Z. Qiu, W. Li, L. Zhu, L. Wang, S. Li, H. Li, W. Lin, M. Yang, and et al. Design and synthesis of benzenesulfonamide derivatives as potent anti-influenza hemagglutinin inhibitors ACS Med Chem Lett 2 2011 603 607
97. K.M. White, P. De Jesus, Z. Chen, P. Abreu Jr, E. Barile, P.A. Mak, P. Anderson, Q.T. Nguyen, A. Inoue, S. Stertz, and et al. A potent anti-influenza compound blocks fusion through stabilization of the prefusion conformation of the hemagglutinin protein ACS Infect Dis 1 2015 98 109
98. J.F. Rossignol, S. La Frazia, L. Chiappa, A. Ciucci, and M.G. Santoro Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level J Biol Chem 284 2009 29798 29808
99. D.A. Engel The influenza virus NS1 protein as a therapeutic target Antivir Res 99 2013 409 416